Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ILMN stock price vs AMGN: inconclusive — current versus $146.48 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Implied fair value · at ILMN's multiple
Needs ILMN P/E.
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 79% equity / 21% debt · EV / Revenue 6.86x · EV proxy / EBITDA proxy 17.71x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ILLUMINA, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
THERMO FISHER SCIENTIFIC INC.
ILMN vs TMO
AGILENT TECHNOLOGIES, INC.
ILMN vs A
DANAHER CORP /DE/
ILMN vs DHR
BIO-RAD LABORATORIES, INC.
ILMN vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
ILMN vs PACB
Natera, Inc.
ILMN vs NTRA
REGENERON PHARMACEUTICALS, INC.
ILMN vs REGN
BIOGEN INC.
ILMN vs BIIB
VERTEX PHARMACEUTICALS INC / MA
ILMN vs VRTX
Gilead Sciences, Inc.
ILMN vs GILD
Moderna, Inc.
ILMN vs MRNA
Eli Lilly and Company
ILMN vs LLY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ILMN can reaccelerate revenue growth and expand operating margins enough to justify a premium multiple versus AMGN, then hold or add; otherwise, the current AMGN comparison argues for caution because ILMN already trades above AMGN-implied range despite weaker growth and profitability.
ILMN trades above AMGN-implied valuation range, with the current price of $199.87 versus an implied price of $156.20, implying -21.9% downside. The gap is driven by ILMN’s higher multiple stack versus AMGN on P/E, EV/EBITDA, and EV/Revenue, even though ILMN has lower leverage.
Supporting Metrics
